Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus GENTACIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus GENTACIDIN.
GENOPTIC vs GENTACIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
5-7 mg/kg IV every 24 hours.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic